Search company, investor...

Acrotech Biopharma

acrotechbiopharma.com

Founded Year

2018

About Acrotech Biopharma

Acrotech Biopharma is a pharmaceutical company which is being built, as a global platform, to develop and commercialize medications, starting with the US market.

Headquarters Location

279 Princeton Hightstown Rd

East Windsor, New Jersey, 08520,

United States

866-850-2876

Missing: Acrotech Biopharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Acrotech Biopharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Acrotech Biopharma Patents

Acrotech Biopharma has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/14/2016

9/13/2022

Transcription factors, Antineoplastic drugs, Histone deacetylase inhibitors, Experimental cancer drugs, Proteins

Grant

Application Date

6/14/2016

Grant Date

9/13/2022

Title

Related Topics

Transcription factors, Antineoplastic drugs, Histone deacetylase inhibitors, Experimental cancer drugs, Proteins

Status

Grant

Latest Acrotech Biopharma News

Aurobindo unit, Evive Biotech ink licensing pact to commercialize CIN treatment product in US

Nov 23, 2022

PTI | New Delhi | Updated: 23-11-2022 12:52 IST | Created: 23-11-2022 12:50 IST Representative image Image Credit: Wikimedia Country: SHARE Aurobindo Pharma on Wednesday said its unit has entered into a licensing pact with Evive Biotech to commercialize Ryzneuta in the US market. The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN). In addition to the US health regulator, Evive 's Marketing Authorization Application (MAA), and New Drug Application (NDA) for Ryzneuta are currently under review by European and Chinese regulators. Neutropenia is a common side-effect of chemotherapy and is a condition characterized by low levels of neutrophils, a type of white blood cell that fights infection. The licensing pact has been inked between Evive and Acrotech Biopharma (Acrotech), a New Jersey-based and wholly-owned subsidiary of Aurobindo Pharma USA Inc, Aurobindo Pharma said in a statement. As part of the agreement, Evive will be responsible for the ongoing development, manufacturing, registration, and supply of Ryzneuta, while Acrotech will use its sales and commercialization capabilities to market and distribute the product in the US, it added. "Ryzneuta provides Acrotech the opportunity to expand its offerings to oncology patients and is aligned with our vision of commercializing scientifically advanced products. Additionally, expanding into CIN creates future growth opportunities for us," Acrotech Biopharma President Ashish Anvekar said. Evive CEO Simon Li said despite the current options, CIN remains a significant clinical condition for most cancer patients, creating the need for more potent and convenient treatment. "Acrotech has proven and strong capacity to commercialize proprietary medications, we look forward to partnering with them for bringing this novel medicine to more cancer patients with CIN in the US,'' he added. Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. (This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) READ MORE ON:

Acrotech Biopharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Acrotech Biopharma Rank

Acrotech Biopharma Frequently Asked Questions (FAQ)

  • When was Acrotech Biopharma founded?

    Acrotech Biopharma was founded in 2018.

  • Where is Acrotech Biopharma's headquarters?

    Acrotech Biopharma's headquarters is located at 279 Princeton Hightstown Rd, East Windsor.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.